Germany's Bayer plans to buy U.S. drug company Merck & Co.'s non-prescription medicine and consumer-care business for $14.2 billion, gaining products such as Claritin allergy pills, Coppertone sun lotion and Dr. Scholl's footcare products.
Bayer CEO Marijn Dekkers said Tuesday that the proposed deal "marks a major milestone on our path towards global leadership in the attractive non-prescription medicines business."
The company said the deal would make it the leader in over-the-counter products in North and Latin America. Bayer already has a major non-prescription division whose brands include Aleve, Alka-Seltzer and One-A-Day vitamins. Bayer also makes prescription drugs, industrial materials and farm chemicals.
Bayer AG said the combined business would be headquartered at Bayer's site in Whippany, N.J. Merck's consumer business has about 2,250 employees and is based in New Jersey.
Merck is headquartered in Whitehouse Station, N.J., and is different from Germany drug company Merck KGaA.
Bayer said it also has entered an agreement with Merck to cooperate on developing and selling drugs known as sGC modulators, which have potential for treating heart failure and pulmonary hypertension. Merck would initially paying Bayer $1 billion under the and further payments contingent on sales.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
